Biotechnology

Compass Pathways

H.C. Wainwright Analyst Trucchio Maintains Buy Rating on COMPASS Pathways, Sets Target Price at $70

Compass Pathways Submits Psilocybin Drug COMP360 for New Drug Application

Compass Pathways released FY2026 Q1 earnings on May 13 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0.7001 (forecast USD -0.4472)

COMPASS Pathways plc Reports Q1 2026 Financials

Jefferies Upgrades Compass Pathways to 'Strong Buy'

Compass Pathways to Release FY2026 Q1 Earnings on May 13 Pre-Market EST, Forecast EPS USD -0.4472

Jefferies Analyst Initiates Buy Rating on COMPASS Pathways

COMPASS Pathways Receives FDA Priority Review for COMP360 Treatment

LifeSci Capital Reiterates Buy Rating on COMPASS Pathways

Compass Pathways Receives FDA Rolling Review Approval for New Drug Application

H.C. Wainwright analyst reaffirms COMPASS Pathways buy rating with a target price of $70.00

Compass Pathways Welcomes White House Directive on Psychedelic Therapy Research

LifeSci Capital Maintains Buy Rating on COMPASS Pathways

Oppenheimer and Morgan Stanley Maintain Buy Rating on COMPASS Pathways

H.C. Wainwright Analyst Reiterates Buy Rating on COMPASS Pathways

Compass Pathways released FY2025 Q4 earnings on March 24 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.004 (forecast USD -0.405)

Compass Pathways released FY2025 Annual Earnings on March 24 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.0785 (forecast USD -2.2618)

Compass Pathways Plans to Submit NDA by End of 2026 and Extend Cash Runway to 2028

Compass Pathways Initiates Regulatory Application for Psilocybin Therapy in the US

TD Cowen Analyst Reiterates Buy Rating for COMPASS Pathways

Agape ATP

Liminatus Pharma

Sunshine Biopharma

Wheeler Real Estate

NewGenIvf

Quantum Cyber NV

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long QBTS Daily ETF

Infleqtion

CMPS

Compass Pathways (NASDAQ:CMPS) is on track to file a New Drug Application for its psilocybin treatment, COMP360, targeting treatment-resistant depression in Q4. Following positive Phase 3 trial results, the company is preparing for an accelerated regulatory timeline. CFO Teri Loxam highlighted the treatment's strong safety profile and efficacy, while Chief Commercial Officer Lori Englebert emphasized its potential to revolutionize psychiatric treatment compared to existing options like Johnson & Johnson’s SPRAVATO.

Market Beat

iShares US Pharma

Johnson & Johnson

Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins

Compass Pathways experienced a significant surge on Monday due to increasing excitement surrounding the company's use of psilocybin in treating treatment-resistant depression. The stock continued to rise in value, bypassing a zone where investors typically take profits. This growing enthusiasm reflects the confidence in Compass Pathways' approach within the market.

Unusual Whales

This Psychedelics Stock Just Keeps Getting Hotter; Why Shares Bypassed A Profit-Taking Zone

RAMP

SHAZ

Stocks are experiencing gap-up moves before the market opens, with LiveRamp Holdings (RAMP) rising 26.7%, Compass Pathways (CMPS) up 20.6%, and SharonAI Holdings (SHAZ) increasing by 13.1%. Meanwhile, stock index futures (SPX) have fallen as traders await Nvidia and retail earnings reports later this week.

LiveRamp

SharonAI

S&P 500

NVIDIA

NVIDIA Corporation

SHARONAI HLDGS INC C/WTS 29/10/2028 (TO PUR COM)

SHARONAI HLDGS INC

At a glance: Stocks gapping up premarket

H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on COMPASS Pathways (CMPS) with a price target of $70.00. Trucchio, a 5-star analyst, has an average return of 25.0% and a 52.75% success rate. The overall analyst consensus for COMPASS Pathways is a Strong Buy, with an average price target of $23.50.

Tip Ranks

AtaiBeckley

Definium Therapeutics

Alnylam Pharma

H.C. Wainwright Sticks to Their Buy Rating for COMPASS Pathways (CMPS)

COMPASS Pathways Plc's American Depository Shares stock price target has been raised to $21.3 from $20.97, indicating a potential upside of 127%. This estimate is based on the analysis of 15 analysts, with price forecasts ranging from $8 to $70 per share. The consensus rating remains a 'Buy' with 14 analysts recommending buys, 1 hold, and no sells. This information is sourced from FactSet and does not constitute investment advice.

TradingView

Factset Research

COMPASS Pathways - American Depository Shares Stock 12‑Month Price Target Raised to $21.3, Implies 127% Upside

Compass Pathways shares are trading higher after the company reported better-than-expected Q1 EPS results.

benzinga_article

Compass Pathways (NASDAQ:CMPS) has initiated a rolling New Drug Application for its psilocybin treatment, COMP360, aimed at treatment-resistant depression, with a potential launch by year-end pending FDA approval. CEO Kabir Nath confirmed alignment with the FDA on the submission process and highlighted positive Phase III study results. The company received a National Priority Voucher, potentially expediting the review timeline. Compass is also preparing for federal and state rescheduling of COMP360 post-approval and is focused on building its commercial organization for a launch in interventional psychiatry treatment centers.

Compass Pathways Q1 Earnings Call Highlights

COMPASS Pathways plc reported a significant revenue increase to $91.2M in Q1 2026, compared to a loss of $17.98M in the same quarter last year. The diluted EPS was ($0.3), an improvement from ($0.24) year-over-year. Key highlights include completion of Phase 3 trials, FDA's rolling review for COMP360, and initiation of a Phase 2b/3 PTSD trial. The company is also preparing for a potential commercial launch, contingent on final Phase 3 data.

COMPASS Pathways plc 1Q 2026: Revenue $91.2M, EPS ($0.3) — 10-Q Summary

Compass Pathways(CMPS.US)